Tag Archive for: Ariceum Therapeutics

Ariceum Therapeutics’ targeted radiopharmaceutical 177Lu-satoreotide exhibits promising clinical response and good tolerability profile in patients with advanced neuroendocrine tumours

/in

95% of patients (36 of 38) treated with Ariceum’s radiopharmaceutical satoreotide achieved disease control in Phase I/II trial That included 21% of patients (8 of 38) who experienced tumour reduction The study, just published in the European Journal of Nuclear Medicine and Molecular Imaging, concluded the treatment “has an acceptable safety profile with a promising […]

Read more

Ariceum Therapeutics doses first patient with its first-in-class targeted radiopharmaceutical drug satoreotide in its Phase Ib study in small cell lung cancer

/in

Ariceum develops satoreotide its first and best-in-class somatostatin receptor 2 antagonist in extensive stage small cell lung cancer Phase Ib study design will be presented at the European Association of Nuclear Medicine Congress 2023 (EANM 2023) in Vienna, Austria on 10th September 2023  Berlin, Germany, 7th September 2023 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical […]

Read more

Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd

/in

Acquisition of next generation radiopharmaceutical clinical pipeline to include Auger-based systemic targeted PARP inhibitor radiation therapies Expansion of operations in the US Acquisition of commercial FDA-approved, diagnostic product NEPHROSCANTM in partnership with GE Healthcare and Ga-68 kit technology IP currently licensed to Novartis Theragnostics’ and Ariceum’s leadership teams to join forces creating a specialist team of […]

Read more

Ariceum Therapeutics Announces Extension of Series A Financing to EUR 47.75M to Advance its Next Generation Radiopharmaceutical Clinical Pipeline

/in

New investors, Andera Partners and Earlybird Venture Capital, join existing investor, Pureos Bioventures raising an additional EUR 22.75 million Funds will be used to advance clinical pipeline and further build Ariceum Therapeutics Olivier Litzka from Andera Partners and Christoph Massner from Earlybird Venture Capital to join the Ariceum non-executive Board of Directors  Berlin, Germany, 18 April […]

Read more

Optimum’s clients are at the forefront of Cancer research

/in

  World Cancer Day is a moment when all of us stop and think of the impact that cancer has on our lives. As the second-leading cause of death worldwide, with 10 million people dying from cancer every year, cancer is a very present healthcare threat. [tag] Macmillan Cancer Support estimates that there are currently […]

Read more